Epigenetic therapies that combine DNA demethylation agents with histone deacetylase (HDAC) inhibitors have demonstrated effectiveness in preclinical studies of non-small-cell lung cancer (NSCLC). This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.